Supplementary Table 5. Cox regression analysis for PFS and OS in patients treated with gemcitabine, cisplatin, and nab-paclitaxel

	PFS		OS	
	HR (95% CI)	*P*-value	HR (95% CI)	*P*-value
Age		0.979		0.896
<65 years old	Reference		Reference	
≥65 years old	1.004 (0.735–1.371)		0.978 (0.697–1.372)	
Sex		0.131		0.330
Female	Reference		Reference	
Male	1.262 (0.933–1.708)		1.177 (0.848–1.636)	
Stage		0.052		0.050
Locally advanced	Reference		Reference	
Metastatic	2.553 (0.991–6.578)		7.358 (0.997–54.302)	
Location		0.519		0.216
Intrahepatic	Reference		Reference	
Gallbladder	1.192 (0.815–1.745)		1.126 (0.760–1.669)	
Extrahepatic	0.955 (0.657–1.386)		0.756 (0.490–1.167)	
Differentiation		0.029		0.387
Well differentiated	Reference		Reference	
Moderately differentiated	1.575 (0.749–3.313)		1.580 (0.670–3.730)	
Poorly differentiated	2.409 (1.122–5.171)		1.919 (0.793–4.643)	
Not assessed	1.600 (0.680–3.764)		1.366 (0.509–3.666)	
Activation of PI3K pathway		<0.001		<0.001
Absent	Reference		Reference	
Present	2.092 (1.397–3.132)		2.014 (1.318–3.078)	

CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; PI3K, phosphoinositide 3-kinase.

 https://doi.org/10.3350/cmh.2025.1019